Apimeds Pharmaceuticals US, Inc.
APUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001894525
No open-market purchases or sales by Apimeds Pharmaceuticals US, Inc. insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $383.7K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 7
- 13F valueReported value at the end of Q2 2026
- $383.7K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding APUS, Q2 2026
No superinvestor reported holding APUS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Apimeds Pharmaceuticals US, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2025 (view filing) | May 13-14 | 2 days | Kim ChristopherChairman and CMO | PPurchaseCommon Stock, par value $0.01 per share | +27.5K | $1.83 | +$50.4K | New position27.5K after | 2 lots |
| May 14, 2025 (view filing)5:52 PM ET | May 12 | 2 days | Inscobee Inc.10% Owner | PPurchaseCommon Stock, par value $0.01 per share | +500.0K | $4.00 | +$2.00M | +33.7%1.98M after | From original |
| May 14, 2025 (view filing) | May 12 | 2 days | Koo JakapDirector | PPurchaseCommon Stock, par value $0.01 per share | +28.5K | $1.99 | +$56.7K | +4.6%643.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Apimeds Pharmaceuticals US, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Hemenway Trust Co LLC | 274,000 | $246.6K | 0.02% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 63,654 | $57.3K | 0.00% | −32,275−33.6% | Reduced |
| Geode Capital Management, LLC | 35,114 | $31.6K | 0.00% | −4,937−12.3% | Reduced |
| Vanguard Fiduciary Trust Co | 24,039 | $21.6K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 15,993 | $14.4K | 0.00% | +15,993 | New |
| UBS Group AG | 11,818 | $10.6K | 0.00% | +7,631+182.3% | Added |
| Tower Research Capital LLC (TRC) | 1,664 | $1.50K | 0.00% | +1,664 | New |
Holders of 5% or more of APUS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Apimeds Pharmaceuticals US, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Inscobee Inc. | 13D/A | 34.30%4.32M shares | 0.00 ppfrom 34.30% | May 19, 20255 filings | May 7, 2026 | SEC |
| Ayrton Capital LLC | 13G | 9.99%1.40M shares | New | Feb 11, 20261 filing | Feb 11, 2026 | SEC |